Financing ·
BioXcel Therapeutics entered into the Eleventh Amendment to its Credit Agreement on July 31, 2026, deferring a…
BTAIBioXcel Therapeutics, Inc.
BioXcel Therapeutics entered into the Eleventh Amendment to its Credit Agreement on July 31, 2026, deferring a $9,016,914.47 principal and interest payment originally due June 30 until August 31, 2026. The amendment reduces the minimum liquidity covenant from $7.5 million to $6.25 million but requires the company to enter into definitive agreements by August 10, 2026, to repay all loans or secure alternative capital acceptable to lenders. Additionally, the company is prohibited from modifying compensation arrangements for directors, officers, or employees through August 10, 2026. BioXcel Therapeutics operates in the biotechnology industry, focusing on the development of pharmaceutical treatments.